Anteris Technologies Commences US Early Feasibility Study
Dr Azeem Latib and his team from Montefiore Health System with Anteris Technologies employees. (Photo: Business Wire)
Dr. Azeem Latib, Director of Interventional Cardiology, Director of Structural Heart Interventions at Montefiore Health System,
The first group of severe aortic stenosis patients treated with DurAVR™ THV had intraoperatively, post-implant EOAs of 2.2cm2, and average mean gradients of 4mmHg.
Dr. Latib commented:
“Having previously traveled to
The EFS Study is evaluating the safety and feasibility of DurAVR™ THV in the treatment of subjects with symptomatic severe native aortic stenosis (AS). Enrolling ≥15 subjects at 7 Heart Valve Centers of Excellence within
The primary endpoint of this Study at 30 days post-implantation will assess safety and device feasibility. This US EFS Study data will pave the way for a pivotal registrational trial.
Wayne Paterson, CEO of Anteris Technologies, commented:
“The successful treatment of these patients in
Dr. Chris Meduri, CMO of Anteris Technologies, added:
“We are pleased with the excellent results achieved by Dr. Latib and the team at Montefiore. We look forward to sharing the results at TCT 2023.”
About Anteris Technologies Ltd (ASX: AVR)
Anteris Technologies Ltd (ASX: AVR) is a structural heart company committed to designing, developing, and commercializing innovative medical devices. Founded in
The Company’s lead product, DurAVR™, is a transcatheter heart valve (THV) for the treatment of aortic stenosis. DurAVR™ THV has been designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons and is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.
DurAVR™ is made using ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue has been used clinically for over 10 years and distributed for use in over 50,000 patients worldwide.
Controlled deployment and accurate placement of DurAVR™ THV is via Anteris’ proprietary ComASUR™ Delivery System. This system allows precision alignment with the heart’s native commissures to achieve optimal valve positioning.
Anteris Technologies is set to revolutionize the structural heart market by delivering clinically superior solutions that meet significant unmet clinical needs.
Authorization and Additional Information
This announcement was authorized by the Board of Directors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230809858863/en/
For more information:
Investor contact (US)
Malini Chatterjee, Ph.D.
Managing Director
Blueprint Life Science Group
+1 917 330 4269
Investor contact (AUS)
Dejan Toracki
Corporate Development
Anteris Technologies
+61 409 340 641
Website www.anteristech.com
Twitter @AnterisTech
Facebook www.facebook.com/AnterisTech
LinkedIn https://www.linkedin.com/company/anteristech
Source: Anteris Technologies Ltd,